慢性鼻窦炎生物靶向药物治疗的研究进展

doi:10.6040/j.issn.1673-3770.1.2022.572

摘要/Abstract

摘要： 慢性鼻窦炎(CRS)是一种鼻腔鼻窦的慢性炎症性疾病,根据其发病机制可分为1型、2型和3型炎症内在型。目前CRS的药物治疗及手术治疗方法均存在发生各种不良反应和并发症的风险,其中部分难治性鼻窦炎虽经适当的药物和手术治疗仍不能取得满意效果并极易复发,严重影响患者的生活质量。生物靶向药物的应用和发展为CRS的治疗提供了一种有效和安全的替代方案。本文着重介绍针对CRS三种炎症内在型的相关细胞因子(包括TNF-α、IL-4、IL-5、IL-13、IgE和IL-17等)的生物靶向药物治疗的研究进展。

关键词: 鼻窦炎, 鼻息肉, 嗜酸性粒细胞, 炎症因子, 生物靶向药物

Abstract: Chronic sinusitis(CRS)is a chronic inflammatory disease of the nasal cavity and sinuses. Based on its pathogenesis, CRS can be divided into type 1, type 2, and type 3 inflammatory intrinsic type. At present, the drug therapy and surgical treatment of CRS have the risk of various adverse reactions and complications; among these cases of refractory sinusitis, some cannot achieve satisfactory results and are prone to recurrence despite appropriate drug and surgical treatment, thus seriously affecting the quality of life of patients. The application and development of biologic targeted drugs provide an effective and safe alternative to the treatment of CRS. This review focuses on the research progress of biologic targeted drug therapy targeting the cytokines associated with the three intrinsic types of CRS inflammation, including TNF-α, IL-4, IL-5, IL-13, IgE, and IL-17.

Key words: Sinusitis, Nasal polyps, Eosinophils, Inflammatory factor, Biologic targeted drug, Treatment

中图分类号:

R765.41

梁旭,史丽. 慢性鼻窦炎生物靶向药物治疗的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 30-35.

LIANG Xu,SHI Li. Research progress in biologic targeted drug therapy for chronic sinusitis[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 30-35.

参考文献

[1] Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020[J]. Rhinology, 2020, 58(Suppl S29):1-464. doi:10.4193/Rhin20.600.
[2] 中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组,中华医学会耳鼻咽喉头颈外科学分会鼻科组.中国慢性鼻窦炎诊断和治疗指南(2018)[J]. 中华耳鼻咽喉头颈外科杂志,2019(2):81-100. doi: 10.3760/cma.j.issn.1673-0860.2019.02.001.
[3] van der Veen J, Seys SF, Timmermans M, et al. Real-life study showing uncontrolled rhinosinusitis after sinus surgery in a tertiary referral centre[J]. Allergy, 2017, 72(2):282-290. doi:10.1111/all.12983.
[4] Deconde AS, Mace JC, Levy J M, et al. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis[J]. Laryngoscope, 2017, 127(3):550-555. doi:10.1002/lary.26391.
[5] Lou H, Meng Y, Piao Y, et al. Predictive significance of tissue eosinophilia for nasal polyp recurrence in the Chinese population[J]. Am J Rhinol Allergy, 2015, 29(5):350-356. doi:10.2500/ajra.2015.29.4231.
[6] Hox V, Lourijsen E, Jordens A, et al. Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper[J]. Clin Transl Allergy, 2020, 3(10):1. doi:10.1186/s13601-019-0303-6.
[7] Cao PP, Wang ZC, Schleimer RP, et al. Pathophysiologic mechanisms of chronic rhinosinusitis and their roles in emerging disease endotypes[J]. Ann Allergy Asthma Immunol, 2019, 122(1):33-40. doi:10.1016/j.anai.2018.10.014.
[8] Zhang N, Van Zele T, Perez-Novo C, et al. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease[J]. J Allergy Clin Immunol, 2008, 122(5):961-968. doi:10.1016/j.jaci.2008.07.008.
[9] Michel O, Dinh PH, Doyen V, et al. Anti-TNF inhibits the airways neutrophilic inflammation induced by inhaled endotoxin in human[J]. BMC Pharmacol Toxicol, 2014,3(15):60. doi:10.1186/2050-6511-15-60.
[10] Malaviya R, Laskin JD, Laskin DL. Anti-TNFalpha therapy in inflammatory lung diseases[J]. Pharmacol Ther, 2017, 180:90-98. doi:10.1016/j.pharmthera.2017.06.008.
[11] Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor[J]. Nat Clin Pract Rheumatol, 2006, 2(11):602-610. doi:10.1038/ncprheum0336.
[12] Van Crombruggen K, Zhang N, Gevaert P, et al. Pathogenesis of chronic rhinosinusitis: inflammation[J]. J Allergy Clin Immunol, 2011, 128(4):728-732. doi:10.1016/j.jaci.2011.07.049.
[13] Lan F, Zhang N, Holtappels G, et al. Staphylococcus aureus Induces a Mucosal Type 2 Immune Response via Epithelial Cell-derived Cytokines[J]. Am J Respir Crit Care Med, 2018, 198(4):452-463. doi:10.1164/rccm.201710-2112OC.
[14] Kohanski MA, Workman AD, Patel NN, et al. Solitary chemosensory cells are a primary epithelial source of IL-25 in patients with chronic rhinosinusitis with nasal polyps[J]. J Allergy Clin Immunol, 2018, 142(2):460-469. doi:10.1016/j.jaci.2018.03.019.
[15] Nagarkar DR, Poposki JA, Tan BK, et al. Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis[J]. J Allergy Clin Immunol, 2013, 132(3):593-600. doi:10.1016/j.jaci.2013.04.005.
[16] Shaw JL, Fakhri S, Citardi MJ, et al. IL-33-responsive innate lymphoid cells are an important source of IL-13 in chronic rhinosinusitis with nasal polyps[J]. Am J Respir Crit Care Med, 2013, 188(4):432-439. doi:10.1164/rccm.201212-2227OC.
[17] Poposki JA, Klingler AI, Tan BK, et al. Group 2 innate lymphoid cells are elevated and activated in chronic rhinosinusitis with nasal polyps[J]. Immun Inflamm Dis, 2017, 5(3):233-243. doi:10.1002/iid3.161.
[18] Nagarkar DR, Poposki JA, Comeau MR, et al. Airway epithelial cells activate TH2 cytokine production in mast cells through IL-1 and thymic stromal lymphopoietin[J]. J Allergy Clin Immunol, 2012,130(1):225-232. doi:10.1016/j.jaci.2012.04.019.
[19] Cao PP, Zhang YN, Liao B, et al. Increased local IgE production induced by common aeroallergens and phenotypic alteration of mast cells in Chinese eosinophilic, but not non-eosinophilic, chronic rhinosinusitis with nasal polyps[J]. Clin Exp Allergy, 2014, 44(5):690-700. doi:10.1111/cea.12304.
[20] Bachert C, Han JK, Wagenmann M, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps(CRSwNP)and biologics: Definitions and management[J]. J Allergy Clin Immunol, 2021,147(1):29-36. doi:10.1016/j.jaci.2020.11.013.
[21] Kim H, Ellis AK, Fischer D, et al. Asthma biomarkers in the age of biologics[J]. Allergy Asthma Clin Immunol, 2017, 17(13):48. doi:10.1186/s13223-017-0219-4.
[22] Bachert C, Wagenmann M, Hauser U, et al. IL-5 synthesis is upregulated in human nasal polyp tissue[J]. J Allergy Clin Immunol, 1997, 99(6 Pt 1):837-842. doi:10.1016/s0091-6749(97)80019-x.
[23] Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial[J]. J Allergy Clin Immunol, 2017, 140(4):1024-1031. doi:10.1016/j.jaci.2017.05.044.
[24] Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis[J]. J Allergy Clin Immunol, 2011, 128(5):989-995. doi:10.1016/j.jaci.2011.07.056.
[25] Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps[J]. J Allergy Clin Immunol, 2006,118(5):1133-1141. doi:10.1016/j.jaci.2006.05.031.
[26] Mitchell P, Leigh R. A drug safety review of treating eosinophilic asthma with monoclonal antibodies[J]. Expert Opin Drug Saf, 2019, 18(12):1161-1170. doi:10.1080/14740338.2019.1675634.
[27] Tamechika SY, Isogai S, Maeda S, et al. Improvement of Chronic Rhinosinusitis and Reduction of the Myeloperoxidase-Antineutrophil Cytoplasmic Antibody Titer in a Patient with Eosinophilic Granulomatosis with Polyangiitis by Additional Mepolizumab[J]. Case Rep Rheumatol, 2021, 29:5561762. doi:10.1155/2021/5561762.
[28] Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma[J]. Allergy, 2019, 74(12):2312-2319. doi:10.1111/all.13875.
[29] Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps(LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials[J]. Lancet, 2019, 394(10209):1638-1650. doi:10.1016/S0140-6736(19)31881-1.
[30] Desrosiers M, Mannent LP, Amin N, et al. Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP[J]. Rhinology, 2021, 59(3):301-311. doi:10.4193/Rhin20.415.
[31] Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma[J]. J Allergy Clin Immunol, 2013, 131(1):110-116. doi:10.1016/j.jaci.2012.07.047.
[32] Pinto JM, Mehta N, Ditineo M, et al. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis[J]. Rhinology, 2010, 48(3):318-324. doi:10.4193/Rhino09.144.
[33] Wu Q, Yuan L, Qiu H, et al. Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials[J]. BMJ Open, 2021, 11(9):e47344. doi:10.1136/bmjopen-2020-047344.
[34] Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis[J]. J Allergy Clin Immunol, 2015, 136(6):1431-1440. doi:10.1016/j.jaci.2015.10.010.
[35] Sel S, Wegmann M, Dicke T, et al. Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme[J]. J Allergy Clin Immunol, 2008, 121(4):910-916. doi:10.1016/j.jaci.2007.12.1175.
[36] Garn H, Renz H. GATA-3-specific DNAzyme - A novel approach for stratified asthma therapy[J]. Eur J Immunol, 2017, 47(1):22-30. doi:10.1002/eji.201646450.
[37] Gauvreau GM, O'Byrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses[J]. N Engl J Med, 2014, 370(22):2102-2110. doi:10.1056/NEJMoa1402895.
[38] Shin HW, Kim DK, Park MH, et al. IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis[J]. J Allergy Clin Immunol, 2015, 135(6):1476-1485. doi:10.1016/j.jaci.2015.01.003.
[39] Teufelberger AR, Nordengrun M, Braun H, et al. The IL-33/ST2 axis is crucial in type 2 airway responses induced by Staphylococcus aureus-derived serine protease-like protein D[J]. J Allergy Clin Immunol, 2018, 141(2):549-559. doi:10.1016/j.jaci.2017.05.004.
[40] Gevaert P, Lang-Loidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps[J]. J Allergy Clin Immunol, 2006, 118(5):1133-1141. doi:10.1016/j.jaci.2006.05.031.
[41] Eidenschenk C, Rutz S, Liesenfeld O, et al. Role of IL-22 in microbial host defense[J]. Curr Top Microbiol Immunol, 2014, 380:213-236. doi:10.1007/978-3-662-43492-5_10.
[42] Nirula A, Nilsen J, Klekotka P, et al. Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases[J]. Rheumatology(Oxford), 2016, 55(suppl 2):i43-i55.doi:10.1093/rheumatology/kew346.
[43] Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma[J]. Am J Respir Crit Care Med, 2013, 188(11):1294-1302. doi:10.1164/rccm.201212-2318OC.
[44] Catley MC, Coote J, Bari M, et al. Monoclonal antibodies for the treatment of asthma[J]. Pharmacol Ther, 2011, 132(3):333-351.doi:10.1016/j.pharmthera.2011.09.005.
[45] Legrand F, Cao Y, Wechsler JB, et al. Sialic acid-binding immunoglobulin-like lectin(Siglec)8 in patients with eosinophilic disorders: Receptor expression and targeting using chimeric antibodies[J]. J Allergy Clin Immunol, 2019, 143(6):2227-2237. doi:10.1016/j.jaci.2018.10.066.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed